$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Globe and Mail, The
VANCOUVER, BC Jan. 30, 2026 /CNW/ -- The global oncology sector is rocketing toward $668 billion in 2034 [1] , partly fueled by a massive structural pivot toward gastrointestinal cancers where clinical velocity is finally shattering historical benchmarks. With the FDA's 2026 framework explicitly prioritizing accelerated pathways for platforms showing superior objective response rates and durability [2] , a select group of innovators is unlocking the immunologically "cold" GI tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ: ONCY), Pfizer (NYSE: PFE), Verastem Oncology (NASDAQ: VSTM), Perspective Therapeutics (NYSE-A: CATX), and RenovoRx (NASDAQ: RNXT) directly at the intersection of pivotal execution and breakthrough immunotherapy. Read more at newswire.ca This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on th
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- $207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswire
- Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal CancerGlobeNewswire
- $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI TumorsPR Newswire
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 2/4/26 - Form 8-K
- 1/20/26 - Form 4
- 1/15/26 - Form 8-K
- ONCY's page on the SEC website